Vancouver, BC, Canada –
Precision NanoSystems Inc. (PNI), a biotechnology company dedicated to helping advance innovative nanotechnology solutions for the molecular understanding and treatment of disease, announced today that it has been recognized by LifeSciencesBC as the Growth Stage MedTech Company of the Year. The award acknowledges that Precision NanoSystems has demonstrated outstanding performance and achieved significant milestones in 2015 and positioned itself well for potential future commercial success.
Paul Drohan, President & CEO of LifeSciences BC said today, “We are extremely fortunate to have such a strong and vibrant life science community to select this year’s winners from. It is a rich pool of highly skilled talent, which makes our selection a difficult task, but once decided, it is a brilliant cross section of our community’s depth of innovation and knowledge-based resources.”
“We feel very privileged to be recognized for this award, particularly with such a deep field and amongst all the growing MedTech companies doing great things here in British Columbia. 2015 was a transformative year for PNI and I’m very proud of our team and the hard work they have dedicated to our efforts. PNI continues to establish itself as the emerging leader of nanomedicine manufacturing technologies and we look forward to many exciting years ahead.“ said James Taylor, CEO & co-founder of PNI. Euan Ramsay, COO & co-founder of PNI added “We achieved significant commercial, technical, and financial milestones in 2015, including growing our team from 10 to 25 engineers, scientists and business professionals. We have installed over 75 NanoAssemblr Benchtop instruments worldwide and many leading biopharma companies are using PNI’s technology for the development of next generation therapeutics.“
About Precision NanoSystems, Inc.
Precision NanoSystems, Inc. (PNI) creates innovative solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI’s proprietary NanoAssemblr platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.